FoCUS and NPC plan to explore Medicaid Best Price reforms required to enable precision financing solutions, including analyzing potential adverse effects on Medicaid. The research will combine a review of … Read More
W2O Named First Pioneer Site for MIT NEWDIGS Initiative
Firm Joins Program for Learning Ecosystems Accelerator for Patient-Centered, Sustainable Innovation (LEAPS) Project to Use Data to Improve the Lives of Patients CAMBRIDGE, MA April 30, 2020 – W2O, the leading … Read More
Payer Perspectives on Gene Therapy Reimbursement
J.F. Barlow; M.W. Courtney; M. Trusheim. Pharmaceutical Executive, 04/2020 The reimbursement of emerging durable and potentially curative cell and gene therapies challenge US payers due to their high upfront costs. … Read More
LEAPS Monthly Recap: March 2020
NEW MEMBER Cytel joins NEWDIGS Initiative at MIT as a Strategic Partner Cytel initially will participate in the new LEAPS project’s Adaptive Point-of-Care (APoC) platform to bring prospective, real-world evidence … Read More
FoCUS Monthly Recap: March 2020
RECAP Paying for Cures Workshop explores challenges faced by payers, and innovative solutions FoCUS held its second Paying for Cures Workshop at MIT, this one focused on the challenges payers … Read More
Adaptive Reimbursement Innovation Unites NEWDIGS’s FoCUS and LEAPS Projects
Systems approach to biomedical innovation enables improved access for patients. FoCUS’s Precision Financing Solutions for durable cell and gene therapies and the LEAPS’s learning ecosystem to optimize therapeutic regimens for … Read More
Cytel joins NEWDIGS Initiative at MIT as a Strategic Partner
Collaboration to accelerate new clinical trial technologies and techniques for disease-focused RWE production CAMBRIDGE, MA March 23, 2020 – Clinical trial biostatistics and advanced data analytics leader Cytel Inc. joined the Massachusetts … Read More
Paying for Cures Workshop explores challenges faced by payers, and innovative solutions
FoCUS held its second Paying for Cures Workshop at MIT on March 10, this one focused on the challenges payers face when considering new cell and gene therapies. The attendees … Read More
Downstream Innovation Part II
December 2019 marked the transition from the LEAPS two-year design and feasibility assessment phase to the rollout of the rheumatoid arthritis in Massachusetts (RA MA) Pilot. Some important themes surrounding … Read More
LEAPS Monthly Recap: February 2020
RESEARCH BRIEF Downstream InnovationPart II: Real-World Discovery LEAPS to Life! December 2019 marked the transition from the LEAPS two-year design and feasibility assessment phase to the rollout of the rheumatoid … Read More